Associate Vice Chancellor, Clinical Innovation & Data Analytics, Rutgers Biomedical and Health Sciences
Associate Director (Clinical Services), Rutgers Cancer Institute of New Jersey
System Director of Medical Oncology, and Oncology Lead for the Combined Medical Group, RWJBarnabas Health
Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Dr. Andy Evens is a physician-scientist who serves as Associate Vice Chancellor for Clinical Innovation & Data Analytics with Rutgers Biomedical and Health Sciences (RBHS) at Rutgers University, Associate Director for Clinical Services of Rutgers Cancer Institute of New Jersey (CINJ), and Medical Director of the Oncology Service Line for RWJBarnabas Health (RWJBH). He works to further the mission of the State’s only NCI-designated Comprehensive Cancer Center by helping to deliver innovative and integrated cancer care across 11 acute care hospitals, and associated oncology practices throughout the State of New Jersey. For RBHS, he provides leadership on innovation, data analytics, and evidence-based decision-making support systems.
Dr Evens is a clinical expert in the field of lymphoid malignancies, including Hodgkin lymphoma and non-Hodgkin lymphoma, as well as autologous stem cell transplantation, cellular therapy, and other novel targeted therapeutics. Locally at RWJBH and CINJ, he is also Co-Director of the Cancer Survivorship Center of Excellence and the Cardio-Oncology Program, and Director of the Oncology Tele-Medicine program. He has been named a Top Doctor in New Jersey 2019 to 2021.
His research is focused on 3 areas: 1) Clinical investigation of novel therapeutic agents, including biomarker discovery; 2) Prognostication, including systems biology analyses; and 3) Health outcomes, including pharmacovigilance, predictive and simulation modeling, and decision making. Over the past 20 years, he has been the principal investigator of >80 cancer clinical trials that have included phase I, II, and III studies, many which have been multicenter investigator-initiated trials studying novel targeted agents. His research has been continuously funded by the National Institutes of Health (NIH) since 2005. This has resulted in 180+ manuscripts in peer-reviewed publications, 300+ research abstracts presented at national/international research symposiums (including 50+ plenary/oral presentations), and 30+ book chapters with an emphasis on biology, prognosis, treatment, and health outcomes.
